Bulletin
Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

Protagonist Therapeutics Inc.

NAS: PTGX

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Protagonist Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

Jan 31, 2023, 6:39 p.m.

PTGX
/zigman2/quotes/205674595/composite

$

13.70

Change

+0.41 +3.09%

Volume

Volume 359,679

Quotes are delayed by 20 min

/zigman2/quotes/205674595/composite

Previous close

$ 12.99

$ 13.29

Change

+0.30 +2.31%

Day low

Day high

$12.91

$13.61

Open

52 week low

52 week high

$6.91

$30.42

Open

Company Description

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartere...

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Valuation

Price to Sales Ratio

57.91

Price to Book Ratio

5.45

Enterprise Value to EBITDA

-2.52

Enterprise Value to Sales

9.04

Efficiency

Total Asset Turnover

0.08

Liquidity

Current Ratio

7.74

Quick Ratio

7.74

Cash Ratio

7.43

Profitability

Gross Margin

89.86

Operating Margin

-471.34

Pretax Margin

-470.27

Net Margin

-458.94

Return on Assets

-37.30

Return on Equity

-43.32

Return on Total Capital

-43.60

Capital Structure

Total Debt to Total Assets

1.68

Officers and Executives

Name Age Officer Since Title
Dr. Dinesh V. Patel 62 2008 President, CEO & Chief Financial Officer
Mr. Asif Ali 47 2022 Chief Financial Officer & Executive Vice President
Ms. Paula O’Connor - - Senior Vice President-Clinical Development
Dr. Mohammad Masjedizadeh - - Chief Technical officer & Executive VP
Dr. Arturo Molina 62 2022 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
11/16/2022 David Y. Liu
Chief R&D Strategy Officer 		35,331   Derivative/Non-derivative trans. at $4.21 per share. 148,743
11/16/2022 David Y. Liu
Chief R&D Strategy Officer 		35,656   Derivative/Non-derivative trans. at $1.16 per share. 41,360
11/16/2022 David Y. Liu
Chief R&D Strategy Officer 		5,999   Derivative/Non-derivative trans. at $1.89 per share. 11,338
11/16/2022 David Y. Liu
Chief R&D Strategy Officer 		9,726   Derivative/Non-derivative trans. at $1.89 per share. 18,382
11/16/2022 David Y. Liu
Chief R&D Strategy Officer 		13,767   Derivative/Non-derivative trans. at $0.87 per share. 11,977
11/15/2022 Arturo Molina
Chief Medical Officer 		21,250   Award at $0 per share. 0
08/23/2022 Dinesh V. Patel
President and CEO; Director 		20,000   Derivative/Non-derivative trans. at $4.21 per share. 84,200
05/04/2022 Dinesh V. Patel
President and CEO; Director 		15,742   Derivative/Non-derivative trans. at $4.21 per share. 66,273
05/03/2022 William D. Waddill
Director 		12,000   Derivative/Non-derivative trans. at $8.59 per share. 103,080
04/26/2022 Dinesh V. Patel
President and CEO; Director 		30,000   Derivative/Non-derivative trans. at $4.21 per share. 126,300
04/26/2022 Suneel Gupta
Chief Development Officer 		40,000   Derivative/Non-derivative trans. at $7.38 per share. 295,200
04/18/2022 Asif Ali
Chief Financial Officer 		13,750   Award at $0 per share. 0
04/14/2022 Dinesh V. Patel
President and CEO; Director 		34,087   Derivative/Non-derivative trans. at $1.89 per share. 64,424
02/28/2022 Dinesh V. Patel
President and CEO; Director 		4,648   Derivative/Non-derivative trans. at $24.28 per share. 112,853
02/28/2022 Suneel Gupta
Chief Development Officer 		649   Derivative/Non-derivative trans. at $24.28 per share. 15,757
02/28/2022 David Y. Liu
Chief R&D Strategy Officer 		2,119   Derivative/Non-derivative trans. at $24.28 per share. 51,449
02/15/2022 Dinesh V. Patel
President and CEO; Director 		31,250   Award at $0 per share. 0
02/15/2022 Suneel Gupta
Chief Development Officer 		12,500   Award at $0 per share. 0
02/15/2022 David Y. Liu
Chief R&D Strategy Officer 		10,000   Award at $0 per share. 0
02/15/2022 Donald A. Kalkofen
Chief Financial Officer 		7,500   Award at $0 per share. 0
/news/latest/company/us/ptgx

MarketWatch News on PTGX

  5. 5 Biotech Stocks That Are Bucking the Selloff

    4:31 a.m. Jan. 19, 2022

    - Barron's Online

  6. Protagonist Therapeutics upgraded to overweight from neutral at J.P. Morgan

    5:47 a.m. Oct. 12, 2021

    - Tomi Kilgore

  8. Protagonist Therapeutics downgraded to neutral from overweight at J.P. Morgan

    5:54 a.m. Sept. 20, 2021

    - Tomi Kilgore

  9. Biotech stocks are a buy — especially these 18 picks

    1:02 p.m. March 13, 2021

    - Michael Brush

  10. Protagonist Therapeutics initiated at overweight with $35 price target at JPMorgan

    10:01 a.m. Jan. 6, 2021

    - Tonya Garcia

  11. Protagonist Therapeutics stock price target raised to $29 vs. $13 at Instinet

    7:22 a.m. May 10, 2019

    - Ciara Linnane

  12. Protagnoist Therapeutics stock price target raised to $17 from $11 at Stifel Nicolaus

    7:16 a.m. May 9, 2019

    - Tomi Kilgore

  13. Protagonist Therapeutics upgraded to buy from hold at Stifel Nicolaus

    7:16 a.m. May 9, 2019

    - Tomi Kilgore

  14. Charting the Market

    8:02 p.m. March 30, 2018

    - Barron's Online

  15. A Biotech Collapses: Is Buying Now ‘Futile’?

    4:05 p.m. March 26, 2018

    - Barrons Blogs

  17. Protagonist Therapeutics started at buy with $32 stock price target at Stifel Nicolaus

    7:22 a.m. Jan. 29, 2018

    - Tomi Kilgore

  18. Charting the Market

    9:36 p.m. June 2, 2017

    - Barron's Online

/news/nonmarketwatch/company/us/ptgx

Other News on PTGX

  3. 10-Q: PROTAGONIST THERAPEUTICS, INC

    5:00 p.m. Nov. 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  9. 10-Q: PROTAGONIST THERAPEUTICS, INC

    4:12 p.m. Aug. 4, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  12. Protagonist: Too Many Red Flags

    9:45 a.m. June 8, 2022

    - Seeking Alpha

  14. 10-Q: PROTAGONIST THERAPEUTICS, INC

    4:07 p.m. May 5, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  18. FFIE, EVOK and ZY among mid-day movers

    12:11 p.m. April 26, 2022

    - Seeking Alpha

  20. Banco Santander, Polaris, Redfin among premarket losers' pack

    7:18 a.m. April 26, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Protagonist Therapeutics, Inc.

7707 Gateway Boulevard

Suite 140

Newark, California 94560-1160

Phone

1 5104740170

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$27.36M

Net Income

$-125.55M

Employees

118.00

Annual Report for PTGX

/news/pressrelease/company/us/ptgx

Press Releases on PTGX

  3. Protagonist Therapeutics Reports Granting of Inducement Award

    4:05 p.m. Nov. 16, 2022

    - PR Newswire - PRF

  8. Protagonist Therapeutics Reports Granting of Inducement Award

    4:53 p.m. Sept. 20, 2022

    - PR Newswire - PRF

  10. Protagonist Therapeutics Reports Granting of Inducement Award

    6:00 a.m. July 19, 2022

    - PR Newswire - PRF

  21. Loading more headlines...
Link to MarketWatch's Slice.